Table 2 Risk of ipsi- and contralateral lung cancer in women with breast cancer compared to women without breast cancer diagnosis.
No. of events | Incidence per 100,000 pyrs | Crude | Adjusteda | |||
|---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | |||
Ipsilateral LC | ||||||
BC | ||||||
No BC | 420 | 46.2 | 1.00 | Ref. | 1.00 | Ref. |
BC | 134 | 71.1 | 1.55 | (1.28–1.88) | 1.55 | (1.27–1.88) |
RT | ||||||
No BC | 420 | 46.2 | 1.00 | Ref. | 1.00 | Ref. |
BC, No RT | 26 | 49.2 | 1.07 | (0.72–1.59) | 0.96 | (0.64–1.42) |
BC, RT | 108 | 79.7 | 1.74 | (1.41–2.15) | 1.82 | (1.47–2.25) |
RT/N-stage | ||||||
No BC | 420 | 46.2 | 1.00 | Ref. | 1.00 | Ref. |
BC, No RT | 26 | 49.2 | 1.07 | (0.72–1.59) | 0.96 | (0.64–1.42) |
BC, RT N0 | 70 | 84.9 | 1.85 | (1.43–2.38) | 1.92 | (1.49–2.47) |
BC, RT N1-3 | 23 | 73.2 | 1.60 | (1.05–2.44) | 1.72 | (1.13–2.61) |
BC, RT N4+ | 8 | 67.3 | 1.49 | (0.74–2.99) | 1.64 | (0.81–3.30) |
BC, RT NX | 7 | 71.3 | 1.57 | (0.74–3.31) | 1.50 | (0.71–3.16) |
Contralateral LC | ||||||
BC | ||||||
No BC | 456 | 50.2 | 1.00 | Ref. | 1.00 | Ref. |
BC | 122 | 64.7 | 1.30 | (1.06–1.58) | 1.31 | (1.07–1.59) |
RT | ||||||
No BC | 456 | 50.2 | 1.00 | Ref. | 1.00 | Ref. |
BC, No RT | 22 | 41.6 | 0.83 | (0.54–1.27) | 0.75 | (0.49–1.16) |
BC, RT | 100 | 73.8 | 1.48 | (1.19–1.84) | 1.55 | (1.25–1.93) |
RT/N-stage | ||||||
No BC | 456 | 50.2 | 1.00 | Ref. | 1.00 | Ref. |
BC, No RT | 22 | 41.6 | 0.83 | (0.54–1.27) | 0.76 | (0.49–1.16) |
BC, RT N0 | 59 | 71.6 | 1.43 | (1.09–1.88) | 1.50 | (1.14–1.96) |
BC, RT N1-3 | 22 | 70.0 | 1.41 | (0.92–2.16) | 1.51 | (0.98–2.31) |
BC, RT N4+ | 5 | 42.1 | 0.85 | (0.35–2.06) | 0.93 | (0.39–2.26) |
BC, RT NX | 14 | 142.6 | 2.90 | (1.70–4.93) | 2.77 | (1.63–4.73) |
